AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00660270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Study NCT00660270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-interferon
Study NCT00660270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02472379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing: Group 1
Description: Writing about experiences with familiar individuals in their lives, once a week for 6 weeks.
Study NCT02472379 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Writing: Group 2
Description: Writing about experiences with familiar places, once a week for 6 weeks.
Study NCT02426528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cultural and Social exposure
Description: The intervention protocol will consist of 24 months of guided exposure and participation in social and cultural activities undertaken in the Casa del Popolo. The participant will be asked to register for a specific type of event (fine arts, performing arts, and social and volunteering activities), duration and date in order that this information can be supplied for further evaluation. Control group participants will be asked to carry on their lives normally and maintain regular cultural and social activity throughout the duration of the study. At twelve months from the beginning of the observation participants of both groups will be checked (intermediate phase).
Study NCT04295096 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Peripheral blood mononuclear cell apheresis
Description: Peripheral blood mono-nuclear cell donation for tumor immunotherapy study of Universal CAR-T cells
Study NCT04166383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vascular Biogenics (VB)-111
Description: 1E13 or 0.7E13 VP via intravenous (IV) infusion on Day 1 of cycle 1 and continue every 6 weeks
Study NCT04166383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg of nivolumab via intravenous (IV) infusion on Day 1 of each cycle starting on cycle 2 and continue every 2 weeks
Study NCT05169216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: Each week, a sheet of tasks to be executed and a diary were provided to verify compliance with the guidelines:~1. Week 0. Familiarization: Information gathering~2. 1st week. Self-knowledge and concentration: To know sports psychology and mental training. Information on beliefs and expectations in sport.~3. 2nd week: To integrate daily mental training.~4. 3rd week. Trust: To consolidate concentration activation. To integrate and build confidence (in oneself and in the team).~5. 4th week. Application to sports tactics: To apply concentration strategies to your sports practice. To know those strategies that provide the best results for each athlete.~6. 5th and 6th weeks: To integrate the content already provided.~7. 7th week. Link with the team: To strengthen the bond between team members.~8. 8th week. Daily routines: To improve the daily routine prior to the competition.~9. 9th and 10th weeks: To integrate the content already provided.
Study NCT03692572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate supplementation
Description: Subjects will drink 70 ml of beet root juice twice a day for 2 weeks.
Study NCT03692572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will drink 70 ml of nitrate depleted placebo juice twice a day for 2 weeks.
Study NCT02966223 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI and HIDA scan
Description: Pre y90 therapy each subject will undergo a HIDA and MRI scan. 3 months post Y90 - Each subject will undergo a second HIDA scan and MRI scan
Study NCT04462341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water Flosser
Description: Device that uses water under pressure to clean around teeth and under the gums
Study NCT04462341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Toothbrush
Description: Plastic handle with nylon bristles to clean teeth
Study NCT04462341 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Toothbrush
Description: Plastic handle with nylon bristles to clean teeth
Study NCT00075088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram (ECG) Intervention
Description: Pre-hospital electrocardiographic (ECG) monitoring with special software to detect myocardial ischemia and to automatically transmit an ECG to the destination hospital emergency department with a voice alarm announcing Incoming ECG from the field and print out in the ED.
Study NCT00075088 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine Clinical Practice
Description: ECG in the ED as part of routine clinical practice.
Study NCT02017639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form:Prefilled syringe of sarilumab solution Route of administration: Subcutaneous injection
Study NCT02017639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Pharmaceutical form:Film-coated 20 mg Tablet Route of administration: oral
Study NCT00504153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Study NCT00504153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01909427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injections (SC) every 4 weeks through Week 12
Study NCT01909427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CNTO 6785 200 mg
Description: CNTO 6785 200 mg SC every 4 weeks from Week 16 through Week 28
Study NCT01909427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 6785 200 mg
Description: CNTO 6785 200 mg SC every 4 weeks through Week 28
Study NCT01909427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 6785 100 mg
Description: CNTO 6785 100 mg SC every 4 weeks through Week 28
Study NCT01909427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 6785 50 mg
Description: CNTO 6785 50 mg SC every 4 weeks through Week 28
Study NCT01909427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 6785 15 mg
Description: CNTO 6785 15 mg SC every 4 weeks through Week 28
Study NCT01909427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: MTX at the same stable dose through Week 32, that participants were receiving prior to screening.
Study NCT04276896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs
Description: Patients will receive approximately 5x10\^6 LV-DC vaccine and 1x10\^8 CTLs via sub-cutaneous injections and iv infusions, respectively.
Study NCT03672708 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cresyl violet
Description: cresyl violet is applicated at the concentration of 0.15% via a spraying catheter to visualize cellular and tissue architecture in the pCLE
Study NCT01259414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solvent with specific gravity less than lipiodol
Description: TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in distilled water and emulsified lipiodol followed embolization with polyvinyl alcohol particles (PVA)
Study NCT01259414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solvent with specific gravity equivalent to lipiodol
Description: TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water,then emulsified with lipiodol followed embolization with polyvinyl alcohol particles (PVA)
Study NCT00093626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00093626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given orally
Study NCT02547818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALZT-OP1a
Description: 1) Mast cell stabilizer, 2) Neuroinflammatory microglial modulator, 3) A-beta oligomerization inhibitor, and 4) anti-inflammatory
Study NCT02547818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALZT-OP1b
Description: Anti-inflammatory
Study NCT02547818 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo ALZT-OP1a
Description: Non-active capsules
Study NCT02547818 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ALZT-OP1a
Description: Non-active capsules
Study NCT02547818 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo ALZT-OP1b
Description: Non-active tablets
Study NCT02547818 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ALZT-OP1b
Description: Non-active tablets
Study NCT01440894 — intervention group
Intervention type: DEVICE
Intervention: Comparison test
Description: Reference Device: Transtek Glass Body Analyzer, GBF-950, accuracy: ±0.1kg and range: 0-180kg.~DUT(Device Under Test): Transtek Glass Body Fat Analyzer, Model: GBF-733-W1, GBF-1012, BF-1039, BF-1041-A, and GBF-950-D.
Study NCT02551887 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Automated Reminder
Description: Automated reminder shown to provider
Study NCT02551887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Reminder Plus Script
Description: Provider sees both reminder and script.
Study NCT02004093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: Loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks
Study NCT02004093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 175 mg/m2 IV every 3 weeks for 6 cycles
Study NCT02004093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 175 mg/m2 IV every 3 weeks for 6 cycles
Study NCT02004093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: 1000 mg/m2 IV Day 1 and 8 of each cycle for 6 cycles
Study NCT01909427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate (MTX)
Description: MTX at the same stable dose through Week 32, that participants were receiving prior to screening.
Study NCT03613662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-102
Description: Injection
Study NCT00115791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSD1235
Description: IV
Study NCT00115791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV
Study NCT02303704 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: multiport antegrade cardioplegia
Description: Cold blood cardioplegia was used for myocardial protection and just before the removal of the aortic cross-clamp, warm blood shot (normo-kalemic) was started through multi-perfusion set attached to cardioplegia cannula in the aortic root and vein grafts.As contraction of heart started the multiport limb attached to cardioplegia cannula was off and cross clamp was removed .The warm perfusion through the vein grafts was continued at controlled pressures of about 50-70 mmHg, flow rate of 10-30ml/min/graft and temperature of 35-37 oC
Study NCT02303704 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic root antegrade cardioplegia
Description: only cold blood cardioplegia was used for myocardial protection without hotshot.
Study NCT02543827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV140
Description: The subjects will receive daily dose of MV140 during 3 or 6 months
Study NCT02543827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The subjects will receive daily dose of placebo during 3 or 6 months
Study NCT02543827 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will receive daily dose of placebo during 3 or 6 months
Study NCT04733339 — intervention group
Intervention type: BEHAVIORAL
Intervention: Secondary Prevention
Description: behavioral changes in dieting and exercising up to one year after clinical discharge
Study NCT04032730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wisepill device
Description: Participants will receive a Wisepill device for TB and ART medications. Participants will receive an exit counselling session prior to being discharged.~Participants will select the content of a text message to be sent when missing a dose as measured by Wisepill non-opening during medication dose-window.~Participants will receive a post-discharge phone call by study staff for the purpose of identifying any early challenges or obstacles. All participants may receive a titrated Wisepill intervention (TWI) consisting of a text message, phone call, and/or study home visit triggered by medication non-adherence as detected by Wisepill non-opening.~All participants will receive a monthly counselling intervention (MCI). Adherence support groups (ASG) will be conducted on a monthly basis.
Study NCT01528813 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Er:YAG laser + amorolfine lacquer
Description: To each compromised ungual unit randomly assigned to this group it will be applied a single session of Er:YAG laser to the ungual lamina in the beginning of study. Onwards, amorolfine lacquer will be applied weekly for a period of 06 months.
Study NCT01528813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amorolfine lacquer
Description: To each compromised ungual unit randomly assigned to this group, it will be applied amorolfine lacquer weekly for a period of 06 months.
Study NCT06211465 — intervention group
Intervention type: PROCEDURE
Intervention: Total joint arthroplasty
Description: Hip or knee total joint arthroplasty
Study NCT01515293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Incision Laparoscopic Appendectomy
Study NCT01515293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional appendectomy
Study NCT01400581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care Intervention
Description: See description of Intervention arm
Study NCT02980120 — intervention group
Intervention type: OTHER
Intervention: SCID-I
Description: The structured clinical interview for DSM-IV Axis I Disorder (SCID-I, German translation, see Wittchen, Zaudig \& Fydrich, 1997) is a semi-structured interview to diagnose AN and BM. It allows a detailed assessment of ED symptoms across different settings and time periods necessary to make an accurate diagnosis.
Study NCT02980120 — intervention group
Intervention type: OTHER
Intervention: EAT
Description: The Eating Attitudes Test (EAT) is a standardized questionnaire of symptoms and concerns related to ED (Garner \& Garfield, 1979, German translation by Steinhausen). The questionnaire consists of 40 items on a six-point Likert scale, providing information
Study NCT02980120 — intervention group
Intervention type: OTHER
Intervention: EDI-2
Description: The Eating Disorder Inventory 2 (Paul \& Thiel, 2004) is a self-report questionnaire on psychological features generally associated with AN and BN.The instrument consists of 91 items on a six-point Likert scale. The 11 scales are drive for thinness, bulimia, body dissatisfaction, ineffectiveness, perfectionism, interpersonal distrust, interoceptive awareness, maturity fears, asceticism (provisional), impulse regulation (provisional) and social insecurity (provisional). It was designed as a diagnostic aid; its psychometrics have been tested, with studies demonstrating satisfactory internal consistency reliability coefficients (between .44 and .93), test-retest reliability of .79 to .95 (after one week) and above .80 (after three weeks), and content, convergent and discriminant validity.
Study NCT02980120 — intervention group
Intervention type: OTHER
Intervention: SCID-II
Description: The SCID-II interview (German, see Wittchen, Zaudig \& Fydrich, 1997) is a widely used and researched instrument to assess DSM-IV-TR personality disorders.The interview covers all ten DSM-IV personality disorders (antisocial, avoidant, borderline, dependent, histrionic, narcissistic, obsessive-compulsive, paranoid, schizoid and schizotypal), PD not otherwise specified, and appendix categories (depressive PD and passive-aggressive PD) and is used to make personality disorder diagnoses either dimensionally or categorically (present-absent). Furthermore, it allows the investigation of patterns of PD that co-occur with other mental disorders as well as the analysis of the underlying structure of personality pathology.
Study NCT02980120 — intervention group
Intervention type: OTHER
Intervention: LoPF
Description: In order to specifically focus on certain personality traits, we use the LoPF as an additional measure. It is a well-validated and reliable self-report questionnaire to measure healthy and pathological personality functioning in adolescents. It is based on the DSM-5 Section III Alternative Model for Personality disorders and covers core impairments in adolescents' personality functioning: identity, self-direction (self-related personality functioning), intimacy/ attachment and empathy/ social-related personality functioning (Sevecke \& Krischer, 2011).
Study NCT02980120 — intervention group
Intervention type: OTHER
Intervention: HAWIK-IV
Description: The Wechsler Intelligence Scale for Children (HAWIK-IV, Petermann \& Petermann, 2008) will be used assess intelligence. For adolescents older than 16.11 years, we will use the German version of the Wechsler Adult Intelligence Scale (HAWIE-IV).Results from test-retest reliability demonstrate that the mean retest scores for all subtests are higher than the mean test scores from first administration, with effect sizes ranging from .08 (comprehension) to .60 (picture completion). The test has demonstrated an acceptable relationship to other measures of achievement, memory, adaptive behavior, emotional intelligence and giftedness in children and adolescents (Canivez, 2014). For the non-clinical adolescent sample, we will use two subtests of the HAWIK.
Study NCT02980120 — intervention group
Intervention type: DEVICE
Intervention: fMRI
Description: To measure food-related brain activation, event-related fMRI will be used, with phases of high-caloric images alternating with phases of low-caloric images and images of fixation cross (not related to food images). A total of 18 blocks will be performed - see figure below. The duration of each phase will be 30 seconds. In a second run, the patients and control subjects will drink chocolate milk and water, alternating every 30 seconds, through a long silicon tube. This procedure was successfully tested in a previous fMRI study with adult AN patients (Gizewski et al. 2010, Vocks et al. 2011) and has now been adopted in preliminary measurements for young AN patients.
Study NCT02871804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined resection of the splenic vein
Description: combined resection of the splenic vein with the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
Study NCT02871804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: separated resection of the splenic vein
Description: separated resection of the splenic vein from the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
Study NCT00518388 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: Focus groups each lasting about 2 hours.
Study NCT00518388 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire relating to your health practices and knowledge about cervical cancer and HPV.
Study NCT01542268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pentoxifylline
Description: Patients will take 800mg/day, via oral, of pentoxifylline. 400 mg of pentoxifylline each 12 hours (during meals time).Period: 3 months.
Study NCT01542268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pentoxifylline placebo
Description: Patients will take 800mg/day, via oral, of pentoxifylline placebo. 400 mg of pentoxifylline placebo each 12 hours (during meals time).Period: 3 months.
Study NCT03765242 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT04426604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Light induced fluorescence intraoral camera
Description: Each restoration margins will be assessed by Light induced fluorescence intraoral camera to assess its validity in diagnosing secondary caries around margins of resin composite restorations
Study NCT04426604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Laser-induced fluorescence device
Description: Each restoration margins will be assessed by Laser-induced fluorescence device to assess its validity in diagnosing secondary caries around margins of resin composite restorations
Study NCT02004093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 mg/m2 IV Day 1 and 8 of each cycle for 6 cycles
Study NCT02004093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Target AUC of 5 following paclitaxel or AUC of 4 following gemcitabine IV every 3 weeks for 6 cycles
Study NCT04426604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual-tactile assessment method according to FDI criteria
Description: Each restoration margins will be assessed by visual-tactile assessment method which includes the use of mirror, probe under good illumination condition to assess its validity in diagnosing secondary caries around margins of resin composite restorations